Crescent Biopharma (CBIO) Other Non-Current Assets (2015 - 2026)
Crescent Biopharma (CBIO) reported Other Non-Current Assets of $1.2 million for Q1 2026, up 983.18% on a QoQ basis from $107000.0 in Q4 2025.
Crescent Biopharma (CBIO) has 12 years of Other Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $107000.0, down 86.84% from the prior year.
- Other Non-Current Assets improved to $1.2 million in Q1 2026 per CBIO's latest filing, from $107000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.2 million in Q1 2022 and bottomed at $50000.0 in Q4 2022.
- The 5-year median for Other Non-Current Assets is $122052.5 (2024), against an average of $451067.7.
- The widest annual swing landed in 2022, when Other Non-Current Assets soared 4145.81%; it then tumbled 97.64% in 2023.
- Tracing CBIO's Other Non-Current Assets over 5 years: stood at $50000.0 in 2022, then surged by 208.35% to $154176.0 in 2023, then soared by 427.32% to $813000.0 in 2024, then plunged by 86.84% to $107000.0 in 2025, then jumped by 983.18% to $1.2 million in 2026.
- Per Business Quant, the three latest CBIO Other Non-Current Assets figures stand at $1.2 million (Q1 2026), $107000.0 (Q4 2025), and $1.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 106,000.00 |
| Dec 31, 2024 | 813,000.00 |
| Sep 30, 2024 | 52,320.00 |
| Jun 30, 2024 | 137,105.00 |
| Mar 31, 2024 | 146,995.00 |
| Dec 31, 2023 | 154,176.00 |
| Sep 30, 2023 | 52,320.00 |
| Jun 30, 2023 | 52,320.00 |
| Mar 31, 2023 | 52,320.00 |
| Dec 31, 2022 | 50,000.00 |
| Sep 30, 2022 | 807,800.00 |
| Jun 30, 2022 | 52,320.00 |
| Mar 31, 2022 | 2.22 Mn |
| Dec 31, 2021 | 1.56 Mn |
| Sep 30, 2021 | 52,320.00 |
| Jun 30, 2021 | 52,320.00 |
| Mar 31, 2021 | 52,320.00 |
| Dec 31, 2020 | 52,320.00 |
| Sep 30, 2020 | 1.56 Mn |
| Jun 30, 2020 | 1.56 Mn |
| Mar 31, 2020 | 1.56 Mn |
| Dec 31, 2019 | 1.56 Mn |
| Sep 30, 2019 | 1.56 Mn |
| Jun 30, 2019 | 52,320.00 |
| Mar 31, 2019 | 1.56 Mn |
| Dec 31, 2018 | 1.56 Mn |
| Sep 30, 2018 | 52,320.00 |
| Jun 30, 2018 | 1.71 Mn |
| Mar 31, 2018 | 204,364.00 |
| Dec 31, 2017 | 204,364.00 |
| Sep 30, 2017 | 52,320.00 |
| Jun 30, 2017 | 759,531.00 |
| Mar 31, 2017 | 759,531.00 |
| Dec 31, 2016 | 52,320.00 |
| Sep 30, 2016 | 52,320.00 |
| Jun 30, 2016 | 696,531.00 |
| Mar 31, 2016 | 696,531.00 |
| Dec 31, 2015 | 696,531.00 |
| Sep 30, 2015 | 696,531.00 |
| Jun 30, 2015 | 696,531.00 |
| Mar 31, 2015 | 696,531.00 |